none32Interferon α (IFNα) prolongs survival of CML patients achieving CCyR and potentially synergizes with TKIs. We report on the molecular status and long term outcome of 121 patients who were treated in Italy between 1986 and 2000 with IFNα based therapy and who obtained CCyR. After a median follow up of 16.5 years, 74 (61%) patients were switched to standard imatinib: 48 (65%) lost the CCyR on IFNα, and 36 (75%) are alive and in CCyR; 26 (35%) were switched to imatinib when they were still in CCyR on IFNα, and all 26 are alive and in CCyR. Forty-seven patients (39%) were never switched to imatinib: 24 (51%) continued and 23 (49%) discontinued IFNα, respectively, and 39/47 (83%) are alive and in CCyR. At last follow-up, the BCR-ABL transc...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Interferon α (IFNα) prolongs survival of CML patients achieving CCyR and potentially synergizes with...
Interferon α (IFNα) prolongs survival of CML patients achieving CCyR and potentially synergizes with...
Interferon (IFN) prolongs survival of CML patients achieving CCyR and potentially synergizes with TK...
Interferon (IFN) prolongs survival of CML patients achieving CCyR and potentially synergizes with TK...
Interferon (IFN) prolongs survival of CML patients achieving CCyR and potentially synergizes with TK...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
Imatinib has become the gold standard therapy for Ph(+) CML, as it induces complete cytogenetic remi...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Interferon α (IFNα) prolongs survival of CML patients achieving CCyR and potentially synergizes with...
Interferon α (IFNα) prolongs survival of CML patients achieving CCyR and potentially synergizes with...
Interferon (IFN) prolongs survival of CML patients achieving CCyR and potentially synergizes with TK...
Interferon (IFN) prolongs survival of CML patients achieving CCyR and potentially synergizes with TK...
Interferon (IFN) prolongs survival of CML patients achieving CCyR and potentially synergizes with TK...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
To determine the impact on minimal residual disease by switching to imatinib chronic phase chronic m...
Imatinib has become the gold standard therapy for Ph(+) CML, as it induces complete cytogenetic remi...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myelo...